56 related articles for article (PubMed ID: 10922994)
1. Regional muramyl tripeptide phosphatidylethanolamine administration enhances hepatic immune function and tumor surveillance.
Karpoff HM; Jarnagin W; Delman K; Fong Y
Surgery; 2000 Aug; 128(2):213-8. PubMed ID: 10922994
[TBL] [Abstract][Full Text] [Related]
2. Effect of ibuprofen on monocyte activation by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (CGP 19835A): can ibuprofen reduce fever and chills without compromising immune stimulation?
Fujimaki W; Griffin JR; Kleinerman ES
Cancer Immunol Immunother; 1993; 36(1):45-51. PubMed ID: 8422667
[TBL] [Abstract][Full Text] [Related]
3. Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.
Maeda M; Asano T; Kleinerman ES
Cancer Immunol Immunother; 1993 Aug; 37(3):203-8. PubMed ID: 8334682
[TBL] [Abstract][Full Text] [Related]
4. A dried preparation of liposomes containing muramyl tripeptide phosphatidylethanolamine as a potent activator of human blood monocytes to the antitumor state.
Sone S; Utsugi T; Tandon P; Ogawara M
Cancer Immunol Immunother; 1986; 22(3):191-6. PubMed ID: 3731204
[TBL] [Abstract][Full Text] [Related]
5. The in situ activation of cytotoxic properties in murine Kupffer cells by the systemic administration of whole Mycobacterium bovis organisms or muramyl tripeptide.
Xu Z; Fidler IJ
Cancer Immunol Immunother; 1984; 18(2):118-22. PubMed ID: 6391654
[TBL] [Abstract][Full Text] [Related]
6. Liposome-encapsulated muramyl tripeptide up-regulates monocyte chemotactic and activating factor gene expression in human monocytes at the transcriptional and post-transcriptional levels.
Asano T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1994 Jan; 38(1):16-22. PubMed ID: 8299114
[TBL] [Abstract][Full Text] [Related]
7. Effect of Adriamycin on liposomal muramyl tripeptide's ability to up-regulate monocyte cytokine expression.
Asano T; Fujimaki W; McWatters A; An T; Matsushima K; Kleinerman ES
Cancer Immunol Immunother; 1993 Nov; 37(6):408-11. PubMed ID: 8242665
[TBL] [Abstract][Full Text] [Related]
8. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine.
Risin D; Kleinerman ES; Umezu Y; Pizzini RP; Balch CM; Pellis NR
Cancer Immunol Immunother; 1995 Jan; 40(1):57-64. PubMed ID: 7828168
[TBL] [Abstract][Full Text] [Related]
9. Optimization and limitations of systemic treatment of murine melanoma metastases with liposomes containing muramyl tripeptide phosphatidylethanolamine.
Fidler IJ
Cancer Immunol Immunother; 1986; 21(3):169-73. PubMed ID: 3698058
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of murine hepatic tumor growth by liposomes containing a lipophilic muramyl dipeptide.
Brodt P; Blore J; Phillips NC; Munzer JS; Rioux JD
Cancer Immunol Immunother; 1989; 28(1):54-8. PubMed ID: 2909283
[TBL] [Abstract][Full Text] [Related]
11. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid).
Kleinerman ES; Raymond AK; Bucana CD; Jaffe N; Harris MB; Krakoff IH; Benjamin R; Fidler IJ
Cancer Immunol Immunother; 1992; 34(4):211-20. PubMed ID: 1537053
[TBL] [Abstract][Full Text] [Related]
12. Systemic activation of macrophages by liposome-entrapped muramyl tripeptide in mice pretreated with the chemotherapeutic agent adriamycin.
Hisano G; Fidler IJ
Cancer Immunol Immunother; 1982; 14(2):61-6. PubMed ID: 6965228
[TBL] [Abstract][Full Text] [Related]
13. Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patients.
Sone S; Utsugi T; Tandon P; Yanagawa H; Okubo A; Ogura T
Cancer Immunol Immunother; 1990; 30(6):357-62. PubMed ID: 2302725
[TBL] [Abstract][Full Text] [Related]
14. Induction of tumouricidal leucocytes by the intranasal application of MTP-PE, a lipophilic muramyl peptide.
Brownbill AF; Braun DG; Dukor P; Schumann G
Cancer Immunol Immunother; 1985; 20(1):11-7. PubMed ID: 3851691
[TBL] [Abstract][Full Text] [Related]
15. Liposomal muramyl dipeptide therapy of experimental M5076 liver metastases in mice.
Phillips NC; Tsao MS
Cancer Immunol Immunother; 1991; 33(2):85-90. PubMed ID: 2036662
[TBL] [Abstract][Full Text] [Related]
16. Activation of antitumor properties in alveolar macrophages from protein-calorie malnourished rats.
Mutsuura S; Sone S; Tsubura E; Tachibana K; Kishino Y
Cancer Immunol Immunother; 1986; 21(1):63-8. PubMed ID: 3080228
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant interleukin-12 immunogene therapy protects against cancer recurrence after liver resection in an animal model.
Jarnagin WR; Delman K; Kooby D; Mastorides S; Zager J; Brennan MF; Blumgart LH; Federoff H; Fong Y
Ann Surg; 2000 May; 231(5):762-71. PubMed ID: 10767798
[TBL] [Abstract][Full Text] [Related]
18. Mifamurtide: a review of its use in the treatment of osteosarcoma.
Frampton JE
Paediatr Drugs; 2010 Jun; 12(3):141-53. PubMed ID: 20481644
[TBL] [Abstract][Full Text] [Related]
19. Imunomodulative effect of liposomized muramyltripeptide phosphatidylethanolamine (L-MTP-PE) on mice with alveolar echinococcosis and treated with albendazole.
Dvoroznáková E; Porubcová J; Snábel V; Fedorocko P
Parasitol Res; 2008 Sep; 103(4):919-29. PubMed ID: 18587669
[TBL] [Abstract][Full Text] [Related]
20. Macrophage inflammatory protein-2 contributes to liver resection-induced acceleration of hepatic metastatic tumor growth.
Kollmar O; Menger MD; Schilling MK
World J Gastroenterol; 2006 Feb; 12(6):858-67. PubMed ID: 16521212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
